# Encompass Health Corporation – Consensus ‘strong_buy’ rating and 27.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/encompass-health-corporation-consensus-strong_buy-rating-and-27.4-upside-potential/4121130268
- Published: 2023-10-20T14:04:08+01:00
- Author: Charlotte Edwards

**Encompass Health Corporation** with ticker code (EHC) have now 9 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘strong_buy’. The range
between the high target price and low target price is between 85 and 77 suggesting
an average Analsyt target price of $81.89. Given that the stocks previous close 
was at $64.27 this would imply there is now a potential upside of 27.4%. There is
a 50 day moving average of $68.30 and the 200 day moving average is $63.38. The 
company has a market cap of 6.35B. The stock price for the company is currently 
63.36 USD

 The potential market cap would be $8,091,700,399 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 19.03, revenue per share of 46.04
and a 6.67% return on assets.

Encompass Health Corporation is a provider of post-acute healthcare service. The
Company manages its operations through its inpatient rehabilitation segment. The
Company is the owner and operator of rehabilitation hospitals. It operates hospitals
in approximately 37 states and Puerto Rico, with concentrations in the eastern half
of the United States and Texas. The Company operates approximately 156 inpatient
rehabilitation hospitals. It provides specialized rehabilitative treatment on an
inpatient basis. The Company’s inpatient rehabilitation hospitals offer specialized
rehabilitative care across an array of diagnoses and deliver comprehensive patient
care services. It also provides rehabilitative care for patients recovering from
injury or illness, using advanced technology and treatments to maximize recovery.
Its hospitals provide a comprehensive interdisciplinary clinical approach to treatment
that leverages technologies and advanced therapies and leads to superior outcomes.

Share on: